Given the fact that oxidized PTH (Figure 1) does not stimulate the PTH receptor anymore to generate cAMP, and is thus most likely biologically inactive [9]–[12], clinical strategies for the treatment of hyperparathyroidism in dialysis patients based on measurements of PTH using classical third generation sandwich ELISA techniques are most likely prone to incorrect decision making. This evidence concerns the gene PTH and hyperparathyroidism.